Lee's Pharmaceutical Holdings Ltd. (950) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Lee's Pharmaceutical Holdings Ltd.

Dawnrays Pharmaceutical Holdings Ltd.

TOT BIOPHARM International Co. Ltd.

Shanghai Henlius Biotech, Inc.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Charmacy Pharmaceutical Co., Ltd.

Antengene Corp. Ltd.

Clover Biopharmaceuticals Ltd.

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.

Transcenta Holding Ltd.

Fusen Pharmaceutical Co., Ltd.

Why is Lee's Pharmaceutical Holdings Ltd. ?

High Management Efficiency with a high ROE of 16.32%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 74.18

Positive results in Jun 25

ROCE(HY) Highest at 5.35%
INVENTORY TURNOVER RATIO(HY) Highest at 2.64 times
INTEREST COVERAGE RATIO(Q) Highest at 2,140.13

With ROE of 14.79%, it has a Very Attractive valuation with a 0.65 Price to Book Value

Over the past year, while the stock has generated a return of -15.38%, its profits have risen by 6.8% ; the PEG ratio of the company is 0.7
At the current price, the company has a high dividend yield of 248.6

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Lee's Pharmaceutical Holdings Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Lee's Pharmaceutical Holdings Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Lee's Pharmaceutical Holdings Ltd.

-100.0%

-0.01

61.24%

Hang Seng Hong Kong

8.25%

0.33

24.66%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

13.55%

EBIT Growth (5y)

13.25%

EBIT to Interest (avg)

74.18

Debt to EBITDA (avg)

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.44

Tax Ratio

21.23%

Dividend Payout Ratio

28.46%

Pledged Shares

Institutional Holding

0.03%

ROCE (avg)

26.07%

ROE (avg)

16.32%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.65

EV to EBIT

4.71

EV to EBITDA

4.43

EV to Capital Employed

0.65

EV to Sales

1.06

PEG Ratio

0.66

Dividend Yield

248.62%

ROCE (Latest)

13.72%

ROE (Latest)

14.79%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company

ROCE(HY)

Highest at 5.35%

INVENTORY TURNOVER RATIO(HY)

Highest at 2.64 times

INTEREST COVERAGE RATIO(Q)

Highest at 2,140.13

CASH AND EQV(HY)

Highest at HKD 303.58 MM

DEBT-EQUITY RATIO (HY)

Lowest at -3.08 %

OPERATING PROFIT(Q)

Highest at HKD 135.94 MM

OPERATING PROFIT MARGIN(Q)

Highest at 19.56 %

NET PROFIT(Q)

Highest at HKD 67.19 MM

EPS(Q)

Highest at HKD 0.11

-1What is not working for the Company

RAW MATERIAL COST(Y)

Grown by 6.8% (YoY

Here's what is working for Lee's Pharmaceutical Holdings Ltd.

Interest Coverage Ratio

Highest at 2,140.13

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Inventory Turnover Ratio

Highest at 2.64 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Operating Profit

Highest at HKD 135.94 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (HKD MM)

Operating Profit Margin

Highest at 19.56 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Net Profit

Highest at HKD 67.19 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

EPS

Highest at HKD 0.11

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (HKD)

Cash and Eqv

Highest at HKD 303.58 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -3.08 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Lee's Pharmaceutical Holdings Ltd.

Raw Material Cost

Grown by 6.8% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales